Market Research Report on Fibroscan CPT Codes 2025
The global medical diagnostics segment is undergoing rapid evolution, and one of the notable advancements in recent years has been the adoption of transient elastography technology, most prominently used in FibroScan devices. The FibroScan tool is essential for noninvasive assessment of liver fibrosis and steatosis, substantially reducing reliance on liver biopsies. In the United States, integration and reimbursement for these procedures hinge critically on Current Procedural Terminology (CPT) codes—a factor that has shaped both market size and momentum. In 2025, the market landscape for FibroScan and its related CPT codes is marked by dynamic shifts, regulatory developments, and strategic investments, all contributing to an ecosystem where this technology is set to redefine standard liver care.
FibroScan technology leverages transient elastography—sending vibrations through the liver tissue to measure stiffness and estimate fibrosis. With chronic liver disease escalating worldwide, ranging from nonalcoholic fatty liver disease (NAFLD) to viral hepatitis and alcoholic liver disease, there is an ever-increasing demand for safe, scalable diagnostic modalities. Experts such as Dr. Jean-Frédéric Blanc, hepatologist at Bordeaux University Hospital, note, “We are now at a point where FibroScan is no longer just a tool for specialists; it is becoming integral in primary care screening protocols.” This change has been directly accelerated by updates to CPT coding, which have improved accessibility and reimbursement avenues for providers.
The CPT coding for FibroScan, specifically 91200 (liver elastography, transient elastography), was issued several years ago by the American Medical Association (AMA). Its impact on the market, however, crystallized only after consistent coverage from private payers and Medicare. Market research data from 2024 into early 2025 shows that annual FibroScan procedure volumes in the US rose by over 20%, propelled by greater CPT code adoption and heightened disease awareness. Industry analysts predict this will continue, as Francesca M. O'Brien, a senior analyst at MedTech Insights, writes, “The CPT code 91200 is a powerful enabler for diffuse liver disease diagnostics penetration. With a validated reimbursement pathway, clinics now adopt FibroScan with minimal financial friction.”
Market trends for FibroScan CPT codes also reveal nuanced regional growth. Urban centers with higher concentrations of gastroenterology and hepatology clinics, such as New York, Los Angeles, and Houston, show peak penetration rates, but rural market expansion is now accelerating. The AMA’s 2024 amendment clarifying documentation requirements for CPT code 91200 has made FibroScan easier for smaller and remote practices to integrate. Telemedicine further complements this—remote patient management platforms increasingly utilize FibroScan as a keystone diagnostic, uploading results directly into electronic health records (EHRs) for rapid clinical decision-making.
In terms of economic value, the US FibroScan CPT code market size is estimated around $450 million in early 2025, with projected annual growth rates exceeding 17% in the next three years. Global market trajectories are also robust, with Europe and APAC regions seeing parallel upticks as their healthcare systems update procedure coding for transient elastography. According to a 2025 report by Grand View Research, the worldwide FibroScan market—including CPT code equivalents—will surpass $1.2 billion in annual revenues by 2027, underpinned by technology advancements and evolving payer policies.
Key players in the FibroScan space are actively refining devices to broaden CPT code utilization. Echosens, the French company that pioneered FibroScan, continues to enhance hardware and software to sync with evolving reimbursement models in the US and Europe. Their latest updates feature portable FibroScan platforms, enabling office-based and off-site screening. Secondary service providers are also innovating, integrating analytic modules to help clinicians interpret results efficiently, particularly useful when CPT codes are bundled with preventative screening programs for populations at high risk for metabolic liver disease.
Shifting payer landscapes are a critical force in the expansion of FibroScan CPT code utilization. In 2025, regional Blue Cross Blue Shield (BCBS) affiliates, UnitedHealthcare, and Aetna have broadened coverage policies, aligning with the American Liver Foundation’s 2024 recommendation for routine NAFLD screening in adults over 35. These endorsements are reshaping adoption curves for liver elastography CPT codes, especially when leveraged within value-based care contracts. As Dr. Sabina Sokol, a reimbursement expert for Health Policy Advisors Inc., observes, “Payer enthusiasm for FibroScan CPT codes represents a convergence of clinical efficacy and cost containment. Providers are incentivized to transition from legacy biopsy methods to noninvasive protocols.”
Regulatory developments also play an influential role in market dynamics. The Centers for Medicare & Medicaid Services (CMS) in their 2025 Physician Fee Schedule proposed an increase in reimbursement rates for CPT 91200, driven by higher cost analyses of advanced elastography equipment and staff training. This move is anticipated to prompt more clinics to invest in FibroScan devices, as upfront capital constraints are mitigated, spurring both volume and geographic reach. Industry watchdogs argue, however, that continued vigilance is required to ensure coding clarity and uniform documentation practices—an area that the American Society for Gastrointestinal Endoscopy (ASGE) highlights in their annual practice guidelines.
Another significant market trend is the extension of FibroScan indicated patient groups. Historically utilized for hepatitis C and cirrhosis management, FibroScan CPT codes now cover a spectrum of conditions including NAFLD, NASH (nonalcoholic steatohepatitis), autoimmune hepatitis, and pediatric liver disorders. Market researchers estimate that the broadening of clinical indications has expanded addressable patient populations by 40% in 2025 compared to three years prior. Analysts expect further expansion as ongoing clinical trials and meta-analyses prompt guideline bodies to incorporate transient elastography as standard-of-care for pre-symptomatic liver disease screening.
From a health economics standpoint, FibroScan CPT codes contribute to significant savings across the care continuum. Liver biopsies, once the diagnostic gold standard, entail hospitalization costs, risk of complications, and patient apprehension. FibroScan’s noninvasive protocol, codified by 91200, trims procedural time, limits complications, and facilitates repeated serial monitoring. A 2024 study published in the Journal of Hepatology illustrated that system-wide adoption of transient elastography reduced per-patient annual diagnostic costs by 33% within large integrated delivery networks (IDNs). Healthcare strategists are thus doubling down on FibreScan CPT code deployment as part of cost reduction initiatives targeting chronic disease management.
The international market for FibroScan CPT-code equivalents echoes many of the US trends but is shaped by local regulatory bodies and payer systems. European countries such as Germany, France, and the UK have integrated transient elastography into their own coding and reimbursement schemes (e.g., OPS codes in Germany, CCAM codes in France). Asia-Pacific markets, particularly Japan and South Korea, are also expanding coverage as they confront rising NAFLD prevalence. Cross-border technology transfer is accelerating, and multinational hospital chains are standardizing FibroScan CPT workflows across branches, using cloud-based data management for unified reporting.
The competitive landscape is heating up. While Echosens retains the largest market share, several emerging players are launching alternative transient elastography technologies, sometimes at lower price points or with enhanced analytics. These technology wars are reflected in aggressive patenting, partnership agreements with diagnostic distributors, and strategic alliances with payer advocacy groups. Venture capital is also pouring into digital health companies aiming to harmonize CPT code billing with integrated liver care management platforms. A 2025 report from Frost & Sullivan indicates venture funding into CPT code-driven liver diagnosis startups tripled over the past 18 months, suggesting long-term confidence in the segment.
Technological convergence is another noteworthy market driver. FibroScan is increasingly bundled with advanced imaging solutions—portable ultrasound, AI-based fibrosis scoring, and cloud-integrated reporting tools. The integration of CPT code billing modules within these platforms enables seamless claim submission, reducing administrative burden for providers. Dr. Alan Tillman, chief technology officer at Medify Diagnostics, comments, “The next phase in FibroScan market development is digital end-to-end workflow. The CPT code is not just a reference number—it’s a strategic lever transforming device adoption, compliance, and population health analytics.”
A parallel trend is the use of FibroScan CPT codes within population health research and clinical trials. Large-scale studies in 2024-2025 increasingly use transient elastography as a primary endpoint or screening tool, leveraging codified billing to ensure comprehensive data capture. This adoption in research settings is propelling demand among contract research organizations (CROs) and academic medical centers, who seek scalable solutions for clinical trial screening and longitudinal patient monitoring.
The rise of precision medicine is also impacting FibroScan CPT code market dynamics. Providers are stratifying patient risk for personalized liver care, using FibroScan as a gatekeeper exam for tailored interventions such as pharmacotherapy initiation or referral for advanced hepatology consultations. CPT code harmonization with clinical risk scores (FIB-4, NAFLD Fibrosis Score) is underway, with EHR vendors updating their platforms to auto-suggest CPT 91200 when coded indicators are present in patient records.
Patient-centricity remains a core theme in the evolving FibroScan market. With noninvasive diagnostics becoming more accessible, patient apprehension decreases, screening rates increase, and earlier interventions are possible. The National Patient Advocate Foundation (NPAF) recently highlighted FibroScan CPT codes in their 2025 annual report as central to enhancing health equity, noting that fee-for-service and value-based models now routinely cover transient elastography for at-risk populations. This advocacy is pushing large IDNs and managed care organizations (MCOs) to integrate FibroScan protocols into standard preventive health checkups.
Emerging data privacy and regulatory compliance challenges are being addressed. As FibroScan CPT code market penetration deepens, device connectivity and reporting platforms must meet stringent HIPAA, GDPR (Europe), and other international data protection standards. Vendors are investing in cybersecurity infrastructure, ensuring that procedure coding data and patient elastography results are securely transmitted and stored, avoiding breaches that could jeopardize reimbursement or legal standing.
One area of ongoing debate concerns CPT code bundling. Policy analysts point out tension between separate and bundled reimbursement for FibroScan procedures when conducted alongside routine abdominal ultrasounds or metabolic workups. The AMA CPT Editorial Panel has proposed new modifier codes to clarify billing practices; stakeholders are actively lobbying for unambiguous guidelines, aiming to prevent undercoding or double-billing. “Billing clarity is paramount to sustaining FibroScan growth,” argues Lisa Chung, director of reimbursement strategy at Global Liver Foundation. “The CPT code’s value derives from its clarity and compliance—it powers not only technology adoption but also system-wide disease management.”
The market is also witnessing greater cross-specialty utilization. While once primarily the domain of hepatologists, endocrinologists, primary care physicians, and even obesity specialists are increasingly using FibroScan equipped with CPT codes to assess liver health in broader metabolic disease contexts. This multi-disciplinary adoption accelerates procedural volumes and justifies further CPT code expansions to encompass broader risk groups—especially amid rising obesity and diabetes rates linked to NAFLD.
Looking into distribution channels, medical device wholesalers, online procurement platforms, and direct-to-provider models are actively scaling up. Many large hospital networks negotiate bulk device purchase agreements contingent on CPT code reimbursement structures, driving price transparency and competitive dynamics in the device supply chain. Wholesalers increasingly provide CPT coding education and onsite implementation training—further lowering barriers for new entrants and high-volume clinics.
Insurance and reimbursement trends forecast further growth. With Affordable Care Act financial incentives for preventive screening procedures intact, and bipartisan Congressional support for liver disease surveillance, FibroScan CPT codes sit at the intersection of public health ambition and private sector investment. This unique position suggests continued expansion, with more insurers aligning policies to American Association for the Study of Liver Diseases (AASLD) guidelines, broadening procedure coverage and patient pathways.
As medical education curricula evolve, training for CPT-coded FibroScan procedures is becoming standard for graduating gastroenterologists, family medicine residents, and nurse practitioners. Academic medical centers are establishing FibroScan clinical rotation modules, and certification exams assess procedural proficiency and coding compliance. This institutional shift ensures robust and compliant market expansion, providing a steady pipeline of providers equipped to operate, interpret, and bill FibroScan examinations efficiently.
In the digital health era, interoperability is critical. FibroScan CPT codes are increasingly referenced in EHR exchange standards, enabling multi-institutional data sharing to support advanced analytics, outcomes research, and public health surveillance. Healthcare IT platforms now partner directly with device manufacturers to create embedded CPT code templates, auto-populating forms for providers and streamlining claims documentation. These shifts address the historical administrative friction associated with emerging diagnostic technologies, smoothing the pathway for continued adoption.
Population health initiatives targeting at-risk demographics—especially in communities of color disproportionately affected by chronic liver disease—are relying heavily on FibroScan CPT-coded services. Outreach programs deploy mobile screening units, equipped with FibroScan devices, submitting CPT-coded claims for Medicare and Medicaid patients. Policymakers advocate further expansion, citing solid outcome data indicating higher screening rates and measurable declines in advanced liver disease diagnoses where mobile elastography is deployed.
The market for FibroScan CPT codes in 2025 illustrates an intersection of clinical innovation, payer adaptation, technology development, and health policy reform. With robust expert endorsement, rapid penetration across care settings, and continuous reimbursement optimizations, FibroScan transient elastography—anchored by CPT code 91200—redefines liver diagnostics as the medical community steadily transitions into the next era of noninvasive, population-scale screening and monitoring.
https://pmarketresearch.com/hc/medical-ai-assisted-ultrasound-system-market/
Comments
Post a Comment